Logo image of BLRX

BIOLINERX LTD-SPONS ADR (BLRX) Stock Fundamental Analysis

NASDAQ:BLRX - Nasdaq - US09071M2052 - ADR - Currency: USD

4.61  +0.08 (+1.77%)

After market: 4.54 -0.07 (-1.52%)

Fundamental Rating

1

BLRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. Both the profitability and financial health of BLRX have multiple concerns. BLRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BLRX has reported negative net income.
In the past year BLRX has reported a negative cash flow from operations.
BLRX had negative earnings in each of the past 5 years.
BLRX had a negative operating cash flow in each of the past 5 years.
BLRX Yearly Net Income VS EBIT VS OCF VS FCFBLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of BLRX (-7.81%) is better than 85.41% of its industry peers.
The Return On Equity of BLRX (-16.29%) is better than 86.67% of its industry peers.
Industry RankSector Rank
ROA -7.81%
ROE -16.29%
ROIC N/A
ROA(3y)-50.4%
ROA(5y)-49.58%
ROE(3y)-191.99%
ROE(5y)-150.4%
ROIC(3y)N/A
ROIC(5y)N/A
BLRX Yearly ROA, ROE, ROICBLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

Looking at the Gross Margin, with a value of 64.90%, BLRX belongs to the top of the industry, outperforming 80.18% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for BLRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLRX Yearly Profit, Operating, Gross MarginsBLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

BLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BLRX has more shares outstanding
BLRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BLRX is higher compared to a year ago.
BLRX Yearly Shares OutstandingBLRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
BLRX Yearly Total Debt VS Total AssetsBLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -11.86, we must say that BLRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.86, BLRX is doing worse than 76.94% of the companies in the same industry.
BLRX has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
BLRX has a worse Debt to Equity ratio (0.41) than 72.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z -11.86
ROIC/WACCN/A
WACC33.54%
BLRX Yearly LT Debt VS Equity VS FCFBLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 2.27 indicates that BLRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.27, BLRX is doing worse than 72.25% of the companies in the same industry.
A Quick Ratio of 2.04 indicates that BLRX has no problem at all paying its short term obligations.
BLRX has a worse Quick ratio (2.04) than 73.33% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 2.04
BLRX Yearly Current Assets VS Current LiabilitesBLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

BLRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.96%, which is quite impressive.
The Revenue has grown by 91.68% in the past year. This is a very strong growth!
EPS 1Y (TTM)90.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
Revenue 1Y (TTM)91.68%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-96.28%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BLRX Yearly Revenue VS EstimatesBLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 5M 10M 15M 20M 25M
BLRX Yearly EPS VS EstimatesBLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLRX Price Earnings VS Forward Price EarningsBLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLRX Per share dataBLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BLRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOLINERX LTD-SPONS ADR

NASDAQ:BLRX (7/2/2025, 8:19:08 PM)

After market: 4.54 -0.07 (-1.52%)

4.61

+0.08 (+1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17 2025-02-17
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change-71.45%
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap17.15M
Analysts100
Price TargetN/A
Short Float %5.5%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.77
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-2.74
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-8.7
FCFYN/A
OCF(TTM)-8.7
OCFYN/A
SpS6
BVpS5.61
TBVpS2.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.81%
ROE -16.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.9%
FCFM N/A
ROA(3y)-50.4%
ROA(5y)-49.58%
ROE(3y)-191.99%
ROE(5y)-150.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.66%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 2.04
Altman-Z -11.86
F-Score4
WACC33.54%
ROIC/WACCN/A
Cap/Depr(3y)23.7%
Cap/Depr(5y)16.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%483.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)91.68%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-96.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.85%
OCF growth 3YN/A
OCF growth 5YN/A